ArticleNature communications2026
Site-specific profiling of structure and function of Igµ B cell receptor glycans.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycosylation orchestrates megakaryocytic fate of hematopoietic stem cells via Wnt-MUC13 signaling.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although N-linked glycans play pivotal roles in the regulation of antibody effector functions, little is known about the composition and functional impact of glycans attached to human B cell receptors (BCR). Here, we describe the site-specific glycosylation profiles of all 4 N-linked glycosylation sites of human Igµ BCRs from primary naive and memory B cells. Our data indicate that the Igµ BCR glycans do not undergo structural changes during transition from naive to memory cells, as healthy donor-derived BCRs from both B cell subtypes carry similar glycans. Conversely, serum IgM antibodies display distinct glycosylation features to Igµ BCRs, which are in part explained by the different molecular form of Igµ BCRs and IgM antibodies. Moreover, using B cell lines expressing defined BCRs, we show that, although the absence of the Igµ BCR N209 glycans reduces antigen binding, the individual glycosylation sites are nonessential for cell surface expression and BCR internalization following BCR triggering. Collectively, we show high conservation of Igµ BCR glycosylation across B cell subsets and limited contribution to BCR expression and function, suggesting BCR glycans may have evolved to support IgM antibody functions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.